Technology
Health
Biotechnology

Epizyme

$11.44
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.77 (-6.31%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Epizyme and other stocks, options, ETFs, and crypto commission-free!

About

Epizyme, Inc. Common Stock, also called Epizyme, is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Read More Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.

Employees
124
Headquarters
Cambridge, Massachusetts
Founded
2007
Market Cap
905.77M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
635.97K
High Today
$12.13
Low Today
$11.42
Open Price
$12.13
Volume
297.67K
52 Week High
$19.55
52 Week Low
$5.14

Collections

Technology
Health
Biotechnology
Cancer Prevention
Medical
Biopharmaceutical
Pharmaceutical
2013 IPO

News

Seeking AlphaMar 12

Epizyme closes $172M capital raise

Epizyme (EPZM +1.4% ) has closed its concurrent offerings of common stock and convertible preferred stock, yielding gross proceeds of $172.5M....

360
MarketBeatMar 10

Stock Price, News, & Analysis for Epizyme

Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP...

46
Seeking AlphaMar 7

Epizyme prices equity offerings; shares down 4% premarket

Epizyme (NASDAQ:EPZM) is down 4% premarket on light volume in reaction to the pricing of its concurrent public equity offerings. 10M shares of common stock at $11.50 per share. Underwriters over-allotment is an additional 1.5M shares. 304,348 shares of non-voting Series A Convertible Preferred Stock at $115 per share. Underwriters over-allotment is an additional 45,652 shares. Closing date for both is March 11. Net proceeds will fund global development and commercialization costs of tazemetostat outside...

131

Earnings

-$0.65
-$0.53
-$0.41
-$0.29
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 7, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.